Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05383001
Title Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AIO-Studien-gGmbH

lung non-small cell carcinoma


Cisplatin + Vinorelbine

Carboplatin + Vinorelbine

Cisplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Carboplatin + Paclitaxel

Cisplatin + Paclitaxel

Cisplatin + Nab-paclitaxel

Durvalumab + Tremelimumab

Carboplatin + Nab-paclitaxel

Cisplatin + Gemcitabine

Carboplatin + Gemcitabine

Age Groups: senior | adult
Covered Countries DEU

Additional content available in CKB BOOST